Tricyclic pyridyl-vinyl pyrroles as PAR1 inhibitors
申请人:Sanofi
公开号:US08871798B2
公开(公告)日:2014-10-28
This disclosure relates to compounds of formula I:
wherein R1, R2, R3, R4, X and Y have the meanings denoted in the disclosure. The compounds of formula I have antithrombotic activity and in particular inhibit the protease-activated receptor 1 (PAR1). The disclosure further relates to a method for producing the compound of formula I and to the use thereof as a pharmaceutical product.
TRIZYKLISCHE PYRIDYL-VINYL-PYRROLE ALS PAR1-INHIBITOREN
申请人:SANOFI
公开号:EP2558465B1
公开(公告)日:2014-12-17
US8871798B2
申请人:——
公开号:US8871798B2
公开(公告)日:2014-10-28
[DE] TRIZYKLISCHE PYRIDYL-VINYL-PYRROLE ALS PAR1-INHIBITOREN<br/>[EN] TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS<br/>[FR] PYRIDYL-VINYL-PYRROLES TRICYCLIQUES UTILISÉS COMME INHIBITEURS DU PAR1
申请人:SANOFI SA
公开号:WO2011128421A1
公开(公告)日:2011-10-20
Die Erfindung betrifft Verbindungen der Formel I, wobei R1, R2, R3, R4, X und Y die in den Ansprüchen bezeichnete Bedeutung haben. Die Verbindungen der Formel I habenantithrombotische Aktivität und 10 inhibieren insbesondere den Protease-aktivierten Rezeptor 1 (PAR1). Die Erfindung betrifft ferner ein Verfahren zur Herstellung der Verbindung der Formel I und deren Verwendung als Arzneimittel.
TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS
申请人:SANOFI
公开号:US20130040943A1
公开(公告)日:2013-02-14
This disclosure relates to compounds of formula I:
wherein R1, R2, R3, R4, X and Y have the meanings denoted in the disclosure. The compounds of formula I have antithrombotic activity and in particular inhibit the protease-activated receptor 1 (PAR1). The disclosure further relates to a method for producing the compound of formula I and to the use thereof as a pharmaceutical product.